TAK-020

CAS No. 1627603-21-7

TAK-020( —— )

Catalog No. M37633 CAS No. 1627603-21-7

TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 377 In Stock
5MG 353 In Stock
10MG 630 In Stock
25MG 1302 In Stock
50MG 1972 In Stock
100MG 3050 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TAK-020
  • Note
    Research use only, not for human use.
  • Brief Description
    TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.
  • Description
    TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    BTK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1627603-21-7
  • Formula Weight
    351.36
  • Molecular Formula
    C18H17N5O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 20.83 mg/mL (59.28 mM; Ultrasonic (<80°C)
  • SMILES
    C=CC(=O)N1CC[C@@H](C1)Oc1nc(cc2ccccc12)-c1nc(=O)[nH][nH]1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Sabat M, et al. Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design. J Med Chem. 2021 Sep 9;64(17):12893-12902. ?
molnova catalog
related products
  • MDVN-1003

    A first-in-class, selective, orally bioavailable, dual inhibitor of BTK and PI3Kδ kinases with IC50 of 32.3 nM and 16.9 nM, respectively.

  • Ibrutinib-biotin

    A chemical probe that consists of Ibrutinib linked to biotin via a long chain linker.

  • Tilfrinib

    Tilfrinib is an effective and selective inhibitor of breast tumor kinase (IC50: 3.15 nM), which displays anti-proliferative activity.